Article Sidebar

pdf
Date Published: 18/09/2023
Abstract Views: 118
Views pdf: 116
DOI: https://doi.org/10.51298/vmj.v530i1.6575
Issue
Vol. 530 No. 1 (2023)
Section
Các bài báo
How to Cite
Đỗ, T. Đạt, Đặng, H. H., & Nguyễn, T. D. (2023). ANTI-MULLERIAN HORMONE LEVELS AND CLINICAL CHARACTERISTICS OF THE PATIENTS WITH GESTATIONAL TROPHOBLASTIC NEOPLASIA TREATED WITH METHOTREXATE REGIMEN AND UTERINE PRESERVATION AT HANOI OBSTETRICS AND GYNECOLOGY HOSPITAL. Vietnam Medical Journal, 530(1). https://doi.org/10.51298/vmj.v530i1.6575

ANTI-MULLERIAN HORMONE LEVELS AND CLINICAL CHARACTERISTICS OF THE PATIENTS WITH GESTATIONAL TROPHOBLASTIC NEOPLASIA TREATED WITH METHOTREXATE REGIMEN AND UTERINE PRESERVATION AT HANOI OBSTETRICS AND GYNECOLOGY HOSPITAL

Tuấn Đạt Đỗ1, Hồng Hải Đặng1,, Tuấn Dương Nguyễn2
1 HMU
2 Hanoi Obstetrics & Gynecology Hospital,

Main Article Content

Abstract

Objectives: Anti-Mullerian hormone (AMH) level and clinical characteristics of the patients with gestational trophoblastic neoplasia (GTN) treated with Methotrexate (MTX) regimen and uterine preservation at Hanoi Obstetrics and Gynecology Hospital. Methods: This prospective, descriptive study included 35 patients with GTN from August 2021 to April 2022. Results: The mean age was 27,1±4,89. Most of the patients did not have enough children with the rate of 68.6%. All patients had FIGO score ≤ 4 and were treated with Methotrexate regimen. The majority of the subjects were either not anemic or only mildly anemic (68.6%). The mean basal AMH level was 2,87 ng/ml (0,96-7,9). Conclusion: Low-risk GTN patients were in childbearing age and categorized by FIGO scores 0-4. The basal AMH level at diagnosis had a significant correlation with patient age.

Article Details

Keywords

gestational trophoblastic neoplasia, AMH (Anti-Mullerian Hormone), MTX (methotrexate).

References

1. Kohorn E.I. (2002). Negotiating a staging and risk factor scoring system for gestational trophoblastic neoplasia. A progress report. J Reprod Med, 47(6), 445–450.
2. Ngan H.Y.S., Seckl M.J., Berkowitz R.S. và cộng sự. (2018). Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynecol Obstet, 143, 79–85.
3. Waterland R.A. và Jirtle R.L. (2004). Early nutrition, epigenetic changes at transposons and imprinted genes, and enhanced susceptibility to adult chronic diseases. Nutrition, 20(1), 63–68.
4. Practice Committee of the American Society for Reproductive Medicine (2015). Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril, 103(3), e9–e17.
5. Dezellus A., Barriere P., Campone M. và cộng sự. (2017). Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer. Eur J Cancer, 79, 72–80.
6. Bi X., Zhang J., Cao D. và cộng sự. (2017). Anti-Müllerian hormone levels in patients with gestational trophoblastic neoplasia treated with different chemotherapy regimens: a prospective cohort study. Oncotarget, 8(69), 113920–113927.
7. Nguyễn T.T.H., Nguyễn Đ.H., và Nguyễn D.Á. (2017). Đánh giá các yếu tố ảnh hưởng đến sự thay đổi của Anti-Mullerian Hormone sau mổ nội soi bóc nang lạc nội mạc tử cung tại buồng trứng. TC Phụ sản, 15(1), 63–68.
8. Fleming R., Kelsey T.W., Anderson R.A. và cộng sự. (2012). Interpreting human follicular recruitment and antimüllerian hormone concentrations throughout life. Fertility and Sterility, 98(5), 1097–1102.